Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target- |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 | |
Prostatic Cancer | Phase 3 | - | 01 Aug 2024 |
Not Applicable | - | - | (Standard of care SRT) | dywhbveoxg(esbpsvyhfg) = No significant differences were found in the rate of MIDs for all QoL domains at 12 and 24 months mlgoltxczk (dzsccizrxy ) View more | - | 01 Oct 2024 | |
Phase 3 | - | 764 | (pN0) | ahncvmmppb(knitafvvwe) = ylrninldqt woiiavybxp (yojkkprdzo ) | Positive | 08 Aug 2022 | |
(pN1) | ahncvmmppb(knitafvvwe) = padlkqkbfw woiiavybxp (yojkkprdzo ) | ||||||
Not Applicable | - | - | hkqyzliofc(uazjejdgdl) = eggojogykw wegbazhyca (rqbfrvbnsh ) View more | - | 15 May 2020 |